Twist Bioscience is now selling a synthetic RNA positive control for the new crown mutant strain Omi Keron (B.1.1.529/BA.1) in order to develop accurate diagnostic tests

South San Francisco, California, USA--(Business Wire)--December 15, 2021--Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers obtain A successful company, the company today announced the launch of a synthetic RNA positive control for the SARS-CoV-2 mutant strain Omi Keron (B.

Dr.

Dr.

To learn more about the products provided by Twist in the fight against COVID-19, including a full set of NGS test panels (panel) that track the emergence of new SARS-CoV-2 strains, please visit https:// research-tools

In March 2020, Twist first launched different SARS-CoV-2 synthetic RNA reference sequences, and is developing next-generation sequencing (NGS) and reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 detection.

The Twist synthetic control is designed based on a specific SARS-CoV-2 variant, covering the complete viral genome, and the sequence has been verified

Customers who purchase synthetic controls must comply with the biosafety inspection protocol led by Twist and applicable laws and regulations

About Twist Bioscience

Twist Bioscience is a leading and fast-growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to promote the industrialization of bioengineering

Legal statement regarding forward-looking statements

This press release contains forward-looking statements